New perspectives for selective NCX activators in neurodegenerative diseases. (May 2020)

• Record Type: Journal Article
• Authors: Annunziato, Lucio; Secondo, Agnese; Pignataro, Giuseppe; Scorziello, Antonella; Molinaro, Pasquale
• Is Part Of: Cell calcium. Volume 87(2020)
• Publication Date: 2020-05
• Subjects: NCX1 -- NCX2 -- NCX3 -- Stroke -- Neurodegenerative diseases -- Drug development; Calcium -- Metabolism -- Periodicals; Vertebrates -- Physiology -- Periodicals; Calcium -- Physiological effect -- Periodicals; Cell physiology -- Periodicals; Calcium in the body -- Periodicals; 572.516
• DOI: 10.1016/j.ceca.2020.102170
• Languages: English
• ISSNs: 0143-4160

Abstract

Graphical abstract: Highlights: Pharmacological modulation of NCX isoforms might be a promising strategy to ameliorate some neurodegenerative diseases. NCX1, NCX2 and NCX3 play a neuroprotective role in stroke damage. NCX3 plays a neuroprotective role in Alzheimer disease, amyotrophic lateral sclerosis and multiple sclerosis. NCX2 inhibition might ameliorate spinal muscular atrophy disease. Abstract: The Na + /Ca 2+ exchanger plays a relevant role in several neurological disorders, thus the pharmacological modulation of its isoforms might represent a promising strategy to ameliorate the course of some neurological pathologies including stroke, neonatal hypoxia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer Disease (AD), and spinal muscular atrophy (SMA). This review will summarize heterocyclic, peptidergic, genetic and epigenetic compounds activating or inhibiting the expression/activity of each NCX isoform. In addition, we will focus our attention on the development of new strategies aimed to ameliorate the pathophysiological conditions in which NCX isoform changes are found.